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Bacillus subtilis CU1 is a recently described probiotic strain with beneﬁcial effects on immune health in
elderly subjects. The following work describes a series of studies supporting the safety of the strain for
use as an ingredient in food and supplement preparations. Using a combination of 16S rDNA and gyrB
nucleotide analyses, the species was identiﬁed as a member of the Bacillus subtilis complex (B. subtilis
subsp. spizizenii). Further characterization of the organism at the strain level was achieved using random
ampliﬁed polymorphic DNA polymerase chain reaction (RAPD PCR) and pulsed ﬁeld gel electrophoresis
(PFGE) analyses. B. subtilis CU1 did not demonstrate antibiotic resistance greater than existing regulatory
cutoffs against clinically important antibiotics, did not induce hemolysis or produce surfactant factors,
and was absent of toxigenic activity in vitro. Use of B. subtilis CU1 as a probiotic has recently been
evaluated in a 16-week randomized, double-blind, placebo-controlled, parallel-arm study, in which
2  109 spores per day of B. subtilis CU1 were administered for a total 40 days to healthy elderly subjects
(4 consumption periods of 10 days separated by 18-day washouts). This work describes safety related
endpoints not previously reported. B. subtilis CU1 was safe and well-tolerated in the clinical subjects
without undesirable physiological effects on markers of liver and kidney function, complete blood
counts, hemodynamic parameters, and vital signs.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Probiotics are deﬁned as live microorganisms that when
ingested in sufﬁcient quantities provide a health beneﬁt to the host
(FAO/WHO, 2001). Current probiotic preparations on the market
are largely represented by species from the Lactobacillus and Biﬁ-
dobacterium genera; however probiotic species from Streptococcus,
Enterococcus and other bacterial species such as Clostridium butyr-
icum and Escherichia coli, and yeast (Saccharomyces cerevisiae) have
a history of safe consumption as probiotic ingredients (Sanders
et al., 2010; Kanai et al., 2015). The use of Bacillus species as pro-
biotics has gained recent interest due to the fact that spore-forming
bacteria, in contrast to vegetative cells, possess a number ofInc. This is an open access article uinteresting characteristics. Speciﬁcally, spores are extremely resis-
tant to heat and desiccation allowing Bacillus probiotics to be stored
at room temperature as dried powdered formulations for extended
periods. Secondly, a wide range of pH stability allows spores to
survive passage through the low pH gastric barrier of the stomach
resulting in the delivery of high numbers of viable microbes to the
lower intestine (Cutting, 2011). Indirect introduction of Bacillus
species to the food supply has occurred for decades through their
use in animal production as feed additives (e.g., B. subtilis) without
evidence of untoward effects on humans (Hong et al., 2005; EFSA,
2014). Probiotic preparations containing Bacillus species (e.g.,
B. clausii, B. coagulans, B. subtilis) have been reported to be effective
in preventing gastrointestinal disorders such as childhood diarrhea
when used prophylactically (Hong et al., 2005), decreasing the
duration of respiratory infections in children (Marseglia et al.,
2007), and overcoming symptoms associated with irritable bowel
syndrome (Tompkins et al., 2010). Bacillus probiotics are currentlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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United States (U.S.), but interest in the West is increasing rapidly
(Cutting, 2011).
Bacillus subtilis is ubiquitous in the environment and can be
isolated from water, soil, air, and decomposing plant matter. Likely
as an indirect result of consuming plant matter, numerous Bacillus
species have also been found in the gastrointestinal tract of animals
(Tam et al., 2006; Hong et al., 2009). The species is an important
source of enzymes used for food, animal feed, and other industrial
applications (Schallmey et al., 2004; Health Canada, 2016), and
several proprietary strains have been marketed as probiotic sup-
plements for human consumption in Asia, Europe, and the U.S
(Cutting, 2011). The mechanism by which Bacillus spores, specif-
ically those of the B. subtilis species, act as probiotics is not well
understood. It is hypothesized that B. subtilis exerts beneﬁcial
probiotic effects, including the production of antimicrobials, stim-
ulation of the immune system, and overall enhancement of gut
microﬂora (Hoa et al., 2001; Casula and Cutting, 2002; Tam et al.,
2006; Dudonne et al., 2015). Members of B. subtilis also have an
established history of use in the preparation of several traditional
fermented foods that have a long history of consumption in
Southeast Asia (e.g., natto) and Africa (e.g., ogiri) (Wang and Fung,
1996), and consumption of these foods is believed to be associ-
ated with numerous health beneﬁts, such as enhanced immunity,
reduced bone loss in post-menopausal women, and anti-allergy
effects (Ouoba et al., 2004; Ikeda et al., 2006; Shurtleff, 2012).
Recently, a newly identiﬁed strain of B. subtilis, CU1 (CNCM I-
2745), has been described as a probiotic in mice (Dudonne et al.,
2015) and an effective probiotic in healthy elderly subjects
(Lefevre et al., 2015). In the clinical study, intermittent consump-
tion of B. subtilis CU1 was found to decrease the occurrence of in-
fectious episodes in healthy free-living elderly subjects during a
period of common infectious disease (i.e., the winter season in
France). The authors attributed these effects to the ability of
B. subtilis CU1 to enhance systemic as well as intestinal and respi-
ratory mucosal immune responses, as indicated by the increased
concentrations of fecal and salivary secretory IgA and serum
interferon-gamma. The safety of this probiotic was assessed by
Lefevre et al. (2015), but full details of the safety data were not
reported.
To determine if a new microbial strain intended for use as aprobiotic is safe for human consumption, a number of regulatory
guidelines and scientiﬁc decision trees have been published to
assist with this task. The European Food Safety Authority (EFSA)
has issued guidelines for the safety assessment of select microor-
ganisms that: a) have an extensive history of use in the food in-
dustry, and; b) for which a wide body of evidence exists
characterizing members of the genus (EFSA, 2007). The Qualiﬁed
Presumption of Safety (QPS) approach, as it is referred to, has been
used by EFSA to evaluate various species of the Bacillus genus and
has speciﬁcally granted QPS status to the B. subtilis species (EFSA,
2015). Therefore, to satisfy QPS status, any new B. subtilis strain
must: i) be identiﬁed at the strain and species level; ii) be absent of
transferable antimicrobial resistances (EFSA, 2012); and iii) lack
toxigenic activity. The Joint FAO/WHO Expert Consultation on
Evaluation of Health and Nutritional Properties of Probiotics in
Food has also published guidelines for the Evaluation of Probiotics
in Food (FAO/WHO, 2002). Within these guidelines, safety con-
siderations outline a number of recommended safety tests for
probiotics in vitro, similar to the QPS recommendations, but also
highlight the importance of conducting human consumption
studies to determine if the probiotic leads to the induction of any
undesirable physiological effects. Taking these regulatory guide-
lines into consideration, Pariza et al. (2015) recently published a
decision tree that summarizes in a step-wise manner how to
conduct thorough safety assessments of microbial cultures inten-
ded for human and animal consumption.
The intent of this present work was to evaluate the safety of
B. subtilis CU1 for human consumption. Studies characterizing the
genomic identity of the strain at the species/subspecies level using
16S ribosomal DNA and gyrase B (gyrB) nucleotide sequencing were
conducted. Unique DNA ﬁngerprints for strain identiﬁcation of the
organismwere obtained using random ampliﬁed polymorphic DNA
(RAPD) polymerase chain reaction (PCR) and pulsed ﬁeld gel elec-
trophoresis (PFGE) analyses. The broth microdilution assay was
used to evaluate resistance against eight clinically important anti-
biotics, and in vitro studies evaluating the capacity of the strain for
synthesis of toxic secondary metabolites with hemolysis and/or
cytotoxic potential were conducted. Human safety endpoints not
previously reported by Lefevre et al. (2015), including analyses of
adverse event reporting, outcomes of clinical chemistry and he-
matological analyses, and measures of vital status are presented
herein. Safety evaluations, both in vitro and in the clinic, demon-
strate that B. subtilis CU1 can be classiﬁed as a non-pathogenic and
non-toxicogenic strain of B. subtilis, andwas safe andwell-tolerated
during repeated consumption in healthy elderly subjects at 2  109
spores/day for a total of 40 days. B. subtilis CU1 was therefore
considered safe and suitable for use as a probiotic ingredient.
2. Materials & methods
2.1. Bacterial strains, culture conditions and supernatants
Bacillus probiotic strains used in this study and their source of
isolation were: B. subtilis CU1 (LifeinU™ Bacillus subtilis CU1/
France) (CNCM I-2745), B. subtilis 26D (Phytosporine®/Ukraine),
B. subtilis Wu-S and Wu-T (ProMarine®/Taiwan), B. subtilis 534
(Sporobacterine®/Russia), B. subtilis DSM 5750 (Bioplus 2B®/
Denmark), B. subtilis (Avi-Bac WS®/Vietnam), B. cereus CIP 5832
(Bactisubtil®/France), B. cereus NCIMB 40112 (Toyocerin®/Spain), B.
coagulans (Avi-Bac WS®/Vietnam), B. licheniformis 31 (Biosporin®/
Ukraine), B. pumilus Nha (Biosubtil®/Vietnam), B. clausii OC
(Enterogermina®/Italy). B. subtilis 168 type strain, B. subtilis 13 GR
LMBA (Laboratoire de Microbiologie et Biochimie Appliquee,
Bordeaux, France) a surfactin producing strain, and the toxin pro-
ducing B. cereus ATCC 14579 and Clostridium difﬁcile VPI 10463
M. Lefevre et al. / Regulatory Toxicology and Pharmacology 83 (2017) 54e6556strains were also used.
Bacillus strains were routinely grown aerobically in Mueller
Hinton (MH) broth (Becton Dickinson (BD), Le Pont de Claix, France)
for 24e48 h, at 30 C or 37 C in a rotary shaker (150 rpm), or in MH
broth supplemented with 1.5% (w/v) agar for plates. To assess the
toxigenic activity of the supernatants, Bacillus strains were also
grown in Luria-Bertani (LB) broth (BD). C. difﬁcile was grown in
Brain Heart Infusion (BHI) broth (BD) supplemented with yeast
extract 1% (w/v) for 3 days at 37 C under anaerobic conditions.
Culture supernatants were harvested by centrifugation at 4 C
(10,000g, 5 min), neutralized, and then ﬁltered (0.2 mm, cellulose
acetate membrane).
Staphylococcus aureus ATCC 29213 was used as a control in the
broth micro-dilution method. It was grown aerobically at 37 C and
frozen stock cultures were stored at 80 C in MH or BHI broth
supplemented with 18% glycerol (v/v).
2.2. Species and strain identiﬁcation
2.2.1. Nucleotide sequence analyses
Genomic DNA from Bacillus strains was prepared as described
previously (Hyronimus et al., 1998). Molecular species identiﬁca-
tion of B. subtilis CU1 was assessed by partial sequencing of the
ribosomal 16S DNA gene (1312 base pairs) and gyrB sequencing
(551 base pairs). Ribosomal 16S RNA was ampliﬁed and sequenced
using the Fpnal (5'-AAGTCGAACGGGGTGTTTA-3') and RPna2 (5'-
CAAACCCGAAGCCGGCTG-3') primers according to the method
described by Chevrot et al. (2008). GyrB was ampliﬁed using the
UP-1 and UP-2r primers (Euroﬁns Genomics, Ebersberg, Germany),
puriﬁed by the NucleoSpin® Gel and PCR Clean-up kit manufac-
tured by Macherey-Nagel (Duren, Germany), and sequenced using
the degenerate UP-1S and UP-2Sr primers and an ABI 3500 genetic
analyzer (Applied Biosystems Inc., Life Technologies SAS, Saint
Aubin, France). The primer sequences used for gyrB ampliﬁcation
(UP-1 and UP-2r) and sequencing (UP-1S and UP-2Sr) were the
same as reported in Yamamoto and Harayama (1995). BLAST ana-
lyses were conducted to compare the resulting 16S rDNA and gyrB
sequences for B. subtilis CU1 to other B. subtilis strains using the
National Center for Biotechnology Information (NCBI) nucleotide
database.
The B. subtilis CU1 genome was assembled using the bioinfor-
matics software Velvet [version 1.2.10] that operates based upon de
novo assembly of reads without any a priori with respect to the
organism being studied (Zerbino and Birney, 2008). A script was
prepared to allow for testing of k-mers from15 to 43 base pairs at 2-
base pair intervals. This script generated 93 contigs ranging from
350 to 450,000 base pairs. This Whole Genome Shotgun project has
been deposited at DDBJ/ENA/GenBank under the accession
MOOX00000000. The version described in this paper is version
MOOX01000000. Following this read assembly, BLAST version
2.2.26 was employed to survey the genome for genes associated
with conferring antibiotic (ermA, ermB, ermC, cfr, tetA, tetK, tetL, tetP,
tetV, qnrA, qnrB, qnrD, qnrS, parC, parE, gyrA, gyrB, aac, rpoB, msrA,
vga, vgB, strA, strB, aphA1, van A, vanB, vanS, vanW) or multidrug
resistance (mdtA, mdtB, mdtC, mdtD, mdtE), as well as genes
implicated in biogenic amine (hdc, tyrA, tyrB) or enterotoxin (cytK,
bceT, hblA, hblB, hblC, hblD, nheA, nheB, nheC) production.
2.2.2. Random ampliﬁed polymorphic DNA (RAPD) PCR
RAPD PCR analysis of B. subtilis CU1 was conducted according to
the method described by Pinchuk et al. (2002). Three 10-mer
primers OPA3 (5'-AGTCAGCCAC -3'), OPL12 (5'-GGGCGGTACT -3'),
and OPH8 (5'-GAAACACCCC-3') (Bioprobe, Montrevils-sous-Bois,
France), were utilized for random ampliﬁcation of DNA segments
using a thermal cycler PTC-200 (MJ Research, Ramsey, U.S.).B. subtilis CU1 was compared to 13 other Bacillus strains, including
some typical commercial probiotic strains. RAPD ampliﬁcations
were repeated at least 3 times for each primer.
2.2.3. Pulsed ﬁeld gel electrophoresis (PFGE)
PFGE analysis was performed according to a protocol adapted
from Marten et al. (2000) combined with the electrophoresis
equipment manufacturer recommendations. Bacillus cells grown in
LB medium without yeast extract were removed from early expo-
nential phase culture, washed with SE buffer (50 mM EDTA,
100 mM Tris-HCl pH 7.2, 20 mM NaCl), and suspended in SE buffer
at a concentration of 2  109 cells/mL. Cells were incorporated into
low melting agarose plugs (Bio-Rad, Richmond, U.S.). To disrupt
cells, the plugswere incubated in different lysis buffers as described
by Marten et al. (2000). For DNA restriction, the plugs were pre-
incubated in restriction SﬁI buffer before adding in 30 units of the
restriction enzyme SﬁI (Thermo Scientiﬁc Fermentas, UK) and
incubated overnight. Plugs were inserted into the wells of a 1%
agarose certiﬁed pulsed ﬁeld gel (Bio-Rad) and digested chromo-
somal DNA was separated by PFGE using a FIGE Mapper Electro-
phoresis system (Bio-Rad). Electrophoresis was conducted with a
forward voltage of 180 V and a reverse voltage of 120 V for 20 h at
ambient temperature with a linear switch time ramp of 0.4e3.5 ms
to inverse pulse. A 5 kb ladder from Bio-Rad was used as molecular
marker and the assay was repeated twice for each strain tested.
2.3. Antibiotic resistance testing
The susceptibility of B. subtilis CU1 to 8 clinically important
antibiotics [chloramphenicol, clindamycin, erythromycin, genta-
micin, kanamycin, streptomycin, tetracycline, and vancomycin:
selected based on the EFSA guidelines for testing antimicrobial
susceptibility of the Bacillus species (EFSA, 2012)] was conducted
using the broth micro-dilution method based on the method
described for Lactobacillus (ISO 10932:2010). Acquired resistance
was established using cut-off values reported within the EFSA
guidance for the assessment of bacterial antimicrobial suscepti-
bility (EFSA, 2012). B. subtilis CU1 was grown in 20 mL MHmedium
under agitation for 24 h at 37 C. Cultures were diluted with MH
medium to a concentration of 1  106 colony forming units (CFU)/
mL and 100 mL of this suspension was added to the wells of a 96-
well plate. S. aureus ATCC 29213 was used as a quality control
strain for the assay. Antibiotics were diluted serially in MHmedium
from a starting concentration of 512-1 mg/L and 100 mL of each
concentration was added to the wells containing bacterial culture.
Plateswere incubated for 48 h at 37 C and theminimum inhibitory
concentration (MIC) for each antibiotic was determined as the
lowest antibiotic concentration inhibiting bacterial growth (i.e.,
absence of turbidity). B. subtilis CU1 growthwas controlled in plates
using MH medium without the addition of antibiotics (presence of
turbidity) whereas negative control wells contained antibiotics
supplemented with MH medium but the bacterial strain was not
inoculated (absence of turbidity). All experiments were conducted
twice.
2.4. Assessment of hemolytic and cytotoxic activity
The hemolytic activity of B. subtilis CU1 was tested according to
the method described by Promdonkoy and Ellar (2003). B. subtilis
CU1 and B. cereus ATCC 14579 were grown in LB and MH liquid
media at 30 and 37 C and cell-free supernatants were collected by
centrifugation. CU1 supernatants were obtained from 3 indepen-
dent cultures and were tested in triplicate. Human blood obtained
from healthy volunteers (EFS Aquitaine, Bordeaux Blood Bank,
France) was centrifuged (2000g, 10 min) to isolate the erythrocytes.
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2.5  108 cells/mL) were combined in the wells of a 96-well poly-
styrene plate. After 3 h of incubation at room temperature, total
released hemoglobin was measured at 415 nm using a Nanodrop
1000 spectrophotometer (Thermo Scientiﬁc, Waltham, U.S.). So-
dium dodecyl sulfate (SDS, 3.47 mM) and B. cereus 14579 super-
natants were used as positive controls and LB and MH broth were
used as negative controls.
Surfactant activity of B. subtilis CU1 was assessed using the
qualitative drop-collapse test described by Bodour and Miller-Maie
(1998). B. subtilis CU1 grown at 37 C for 72 h in LB and MH solid
media, as well as in the same liquid media, was tested for bio-
surfactant production by placing a small drop (5 mL) of each cell
suspension (one colony suspended in 150 mL of demineralized
water), or 5 mL of culture supernatants, in wells coated with 2 mL of
oil (Elf 700 Diesel 10W40). Crystal violet dye (1 mL) was added to
each sample after 1 min to assist with visualizing the drops with
the aid of a magnifying glass. B. subtilis 13 GR, a surfactin producing
strain, was used as a positive control, and distilled water as a
negative control. The result was considered positive when the drop
was ﬂat and negative when drops were rounded, indicating a lack
of biosurfactant production. Three independent cultures of the CU1
strain for each culture media (LB and MH) were analyzed in
triplicate.
Cytotoxic activity of B. subtilis CU1 was evaluated on Vero cells
(Sigma-Aldrich, Lyon, France) by analyzing cell detachment as
previously reported (Saotome et al., 1989). Vero cells, a well-
established cell line used extensively for cytotoxicity testing, were
grown in Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Sigma-
Aldrich), supplemented with 10% (v/v) of heat-inactivated fetal
bovine serum (Gibco, Thermo Scientiﬁc), 0.5% (v/v) of penicillin and
streptomycin (Sigma-Aldrich), and 1% (v/v) of nonessential amino
acids (Sigma-Aldrich). A cellular suspension of 105 cells was seeded
into 12-well culture plates containing 2 mL of cell culture medium
and incubated until conﬂuence. B. subtilis CU1 supernatants
(100 mL) from LB andMHmedia overnight cultures grown at 30 and
37 C were added to the Vero cells and incubated for 3 h at 37 C.
Cells were stained with crystal violet solution as described by
Lefevre et al. (2015) to measure cell detachment. Absorbance was
measured at 650 nm and the percentage of attached cells wasTable 1
BLAST analysis outcomes for 16S rDNA and gyrB sequences from Bacillus subtilis CU1.
Rankb Species name Se
Sequence homology of Bacillus subtilis CU1 16S rRNA (1312 nucleotides) with othe
1 Bacillus subtilis subtilis DS
2 Bacillus subtilis spizizenii NR
3 Bacillus mojavensis IFO
4 Bacillus tequilensis 10
5 Bacillus vallismortis DS
6 Bacillus velezensis BC
7 Bacillus amyloliquefaciens NB
8 Bacillus atrophaeus JCM
9 Bacillus siamensis PD
10 Bacillus methylotrophicus CB
Sequence homology of Bacillus subtilis CU1 gyrB (551 nucleotides) with other Baci
1 Bacillus subtilis subsp. spizizenii TU
2 Bacillus subtilis subsp. spizizenii BC
3 Bacillus subtilis subsp. subtilis BC
4 Bacillus subtilis BC
5 Bacillus subtilis BC
6 Bacillus subtilis BC
7 Bacillus vallismortis BC
8 Bacillus mojavensis BC
9 Bacillus mojavensis BC
10 Bacillus mojavensis DH
a Compared to the NCBI nucleotide database.
b Out of a total of 100 homologous sequences reported.calculated as 100  (A/Ac), where A is the absorbance of treated
cells and Ac is the absorbance of untreated control cells. B. cereus
14579 and C. difﬁcile CD VPI 10463, bacteria that produce cytotoxic
factors, were used as positive controls, and MH medium was used
as a negative control. CU1 supernatants were obtained from 3 in-
dependent cultures and the cytotoxicity test was repeated 3 times.2.5. Human safety assessment
2.5.1. Subjects
B. subtilis CU1 consumption was recently assessed in healthy
free-living elderly subjects in a randomized, double-blind, placebo-
controlled, parallel-arm clinical study (Lefevre et al., 2015). Brieﬂy,
100 elderly subjects (60e74 years of age) were divided into placebo
(39 females, 11 males; n ¼ 50) and probiotic (40 females, 10 males;
n ¼ 50) groups. The mean age of the placebo and probiotic groups
was 63.0 and 63.3 years, respectively. Consumption of dietary
supplements and probiotics was not allowed for 2 and 1 months
leading up to the start of the study, respectively, as well as for the
duration of the study.2.5.2. Experimental design
The study duration was 16 weeks in total, comprised of four
consumption periods of 10 days each, each separated by 18-day
washout periods. During the consumption period, subjects in the
probiotic group (n ¼ 50) consumed one B. subtilis CU1 capsule per
day containing 2  109 spores of B. subtilis CU1 (Lesaffre Human
Care, Marcq en Baroeul, France). The probiotic capsules contained
the active ingredient (95% B. subtilis spores and 5% B. subtilis
vegetative cells) mixed with the following excipients: maltodextrin
DE14, dicalcic phosphate, magnesium stearate, and colloidal silica.
Participants in the placebo group (n ¼ 50) were supplied with
capsules containing only the excipient mix and all subjects were
instructed to consume one capsule daily, 40 min before eating
breakfast. Full study details and evaluation of the ability of B. subtilis
CU1 to stimulate the immune system and promote resistance to
common infectious diseases were previously reported by Lefevre
et al. (2015).quence reference Score % Homology
r Bacillus strainsa
M 10 2412 99
RL B-23049 2409 99
15718 2407 99
b 2401 99
M 11031 2396 99
RC 17467 2390 99
RC 15535 2385 99
9070 2374 99
-A10 2359 99
MB 205 2331 99
llus strainsa
-B-10 913 97
RC 17366 913 97
RC 10255 863 95
RC 17433 857 95
RC 17435 852 95
RC 14714 857 95
RC 17183 802 93
RC 17124 734 91
RC 17531 734 91
T-13 503 91
Fig. 1. DNA ﬁngerprints of B. subtilis CU1 and other Bacillus strains obtained by RAPD
analysis with A) OPA3 primer, B) OPL12 primer, or C) OPH8 primer. Bacillus strains
tested: (a) B. subtilis 168; (b, c) B. subtilis CU1; (d) B. subtilis 26D Phytosporine®; (e, f)
B. subtilisWu-S and Wu-T ProMarine®; (g) B. subtilis 534 Sporobacterine®; (h) B. subtilis
DSM 5750 Bioplus 2B®; (i) B. subtilis Avi-Bac WS®; (j) B. cereus CIP 5832; (k) B. cereus
NCIMB 40112 Toyocerin®; (l) B. coagulans Avi-Bac WS®; (m) B. licheniformis 31 Bio-
sporin®; (n) B. pumilus Nha Biosubtil®; (o) B. clausii OC Enterogermina®. M, molecular
weight marker (Kbp), Lambda EcoRI/HindIII ladder.
Fig. 2. PFGE of B. subtilis CU1 compared to other Bacillus strains. All samples were
digested with a SﬁI restriction enzyme prior to loading on the gel. Bacillus strains
tested: (1) B. subtilis 168; (2, 3) B. subtilis CU1; (4) B. subtilis 26D, Phytosporine®; (5)
B. subtilis 534 Sporobacterine®; (6) B. subtilis DSM 5750 BioPlus 2B®; (7) B. subtilis Avi-
Bac WS®; (8) B. licheniformis 31, Biosporin®; (9) B. clausii OC Enterogermina®. M,
molecular weight marker (Kbp).
M. Lefevre et al. / Regulatory Toxicology and Pharmacology 83 (2017) 54e65582.5.3. Safety assessment
A number of safety parameters were also evaluated during the
trial, including the occurrence of adverse events, measurement of
hematology, clinical chemistry, and hemodynamic parameters;
however, the results of these analyses were not previously pub-
lished by Lefevre et al. (2015). Therefore the methods and results
of these assessments are reported herein. The occurrence of
adverse events was documented by the investigators in the case
report forms for each subject. The association of each adverse
event with study participation was ranked by the investigators asnot likely, possible, likely, or certain, and the intensity of each
adverse event was classiﬁed by the investigators as mild (no
restriction of daily activities), moderate (partial restriction of
daily activities), or severe (inability to achieve daily activities).
Blood was collected into EDTA-coated tubes and serum collection
tubes at baseline (1e2 weeks before the start of the study) and at
study endpoint (week 16) for complete blood counts and evalu-
ation of liver and kidney markers. Whole blood was analyzed
using a CELL-DYN 3200 SL hematology analyzer (Abbott Labo-
ratories, Taguig City, Philippines) to obtain standard complete
blood count data. Clinical chemistry parameters were evaluated
in the serum samples using a Roche Hitachi 911 chemistry
analyzer according to the Roche Diagnostics (Mannheim, Ger-
many) kit protocols as follows: alanine transaminase (ALT), UV
test; aspartate transaminase (AST), UV test; creatinine, enzymatic
colorimetric test; gamma-glutamyltransferase (GGT), enzymatic
colorimetric test; urea, kinetic UV test. Hemodynamic parame-
ters, including arterial pressure and heart rate, were evaluated on
the ﬁrst day of the study (prior to probiotic consumption),
halfway through the study (day 56/week 8), and at the end of the
study (day 112/week 16).
Table 2
Minimum inhibitory concentrations for eight antibiotics tested against Bacillus subtilis CU1.
Antibiotica Minimum inhibitory concentration (mg/L)
Test sample Reference Control
B. subtilis CU1b
(S ¼ susceptible)
Bacillus break points (EFSA, 2012) S. aureus ATCC 29213c
Chloramphenicol 8d (S) 8 16 (2e16)
Clindamycin 2, 4 (S) 4 0.25 (0.06e0.25)
Erythromycin <0.5 (S) 4 1 (0.25e1)
Gentamicin <0.5 (S) 4 1 (0.12e1)
Kanamycin 8 (S) 8 4 (1e4)
Streptomycin 8 (S) 8 ND
Tetracycline <0.5 (S) 8 1 (0.12e1)
Vancomycin <0.5 (S) 4 2 (0.5e2)
MIC ¼ minimum inhibitory concentration; ND ¼ not determined.
a Test concentration range of 0.5e256 mg/L.
b B. subtilis CU1 test concentration 5  105 CFU/mL.
c Values in brackets are MIC reference ranges for S. aureus ATCC 29213 (CLSI, 2011).
d Results were measured in 2 experiments. If different MICs were measured between experiments, both MICs have been reported.
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2.6.1. In vitro studies
Statistical analysis of all in vitro data was performed using
GraphPad Prism® Software version 6.0 for Windows (San Diego,
U.S.). Two-tailed Student's t-tests were performed for comparisons
between the different groups.
2.6.2. Human study
As outlined in the original study plan (Lefevre et al., 2015), all
clinical data were analyzed using SAS® software version 9.1.3 Ser-
vice Pack 4 (SAS Institute Inc., Cary, U.S.) and results were expressed
as mean ± SD. Statistical signiﬁcance was set at P < 0.05. The
number of subjects with at least one adverse effect, the association
of adverse events with study participation, and the severity of
adverse events were compared between the probiotic and placebo
groups using the chi-square test or Fisher's exact test.
3. Results
3.1. Species and strain identiﬁcation
A total of 1312 nucleotides of 16S rDNA of B. subtilis CU1 were
sequenced. The obtained sequence was compared to the 16S rDNA
sequences deposited in the NCBI nucleotide database, and strong
homology was found between B. subtilis CU1 and Bacillus subtilisTable 3
Toxigenic activity testing of Bacillus subtilis CU1.
Hemolytic activitya
Test substance
B. subtilis CU1 Negative
Negative controls
LB medium Negative
MH medium Negative
Distilled water N/A
Positive controls
Bacillus cereus 14579 Positive
SDS Positive
B. subtilis 13 GR N/A
Clostridium difﬁcile CD VPI N/A
N/A ¼ not applicable.
a Total released hemoglobin from erythrocytes was measured at 415 nm using a Nano
b Measured using the drop-collapse method.
c Measured using the crystal violet staining assay; determined as a measure of cell viasubsp. subtilis and Bacillus subtilis subsp. spizizenii (Table 1). Mo-
lecular identiﬁcation of B. subtilis CU1 to a species level was
determined by sequencing gyrB (551 base pairs), and when
compared to the NCBI nucleotide database, characterization of the
strain at the subspecies level as Bacillus subtilis subspecies spizizenii
was suggested by the high homology to two spizizenii isolates
(Table 1).
Characterization of B. subtilis CU1 at the strain level was con-
ducted using RAPD PCR analysis with three different primers. The
RAPD method was sufﬁciently robust to distinguish the strain from
13 other Bacillus reference strains and this differentiationwas most
clear with the OPA3 and OPL12 primers (Fig. 1A and B). The OPH8
primer did not generate as unique a banding pattern for B. subtilis
CU1 (Fig. 1C). Similarly, the PFGE proﬁle of B. subtilis CU1 (lanes 2 &
3, Fig. 2) was clearly distinguishable from ﬁve commercially avail-
able probiotic strains of B. subtilis (lanes 1, 4e7, Fig. 2) and distinct
banding patterns were observed for B. subtilis CU1 relative to
B. licheniformis and B. clausii (lanes 8 & 9, Fig. 2). The molecular
typing methods used showed that strain-speciﬁc proﬁles could be
obtained for the B. subtilis CU1 strain. Two different batches of
B. subtilis CU1 that were produced in consecutive years were
included in the RAPD and PFGE analyses (see lanes b & c of Fig. 1
and lanes 2 & 3 of Fig. 2) and were determined to be identical in
their genotypic analyses. The results for the RAPD and PFGE ana-
lyses shown in Figs. 1 and 2 are representative of multiple
evaluations.Surfactant productionb Cytotoxic activityc
Negative Negative
N/A N/A
N/A Negative
Negative N/A
N/A Positive
N/A N/A
Positive N/A
N/A Positive
drop 1000 spectrophotometer.
bility of Vero cells.
Fig. 3. Assessing the toxigenic activity of B. subtilis CU1. B. subtilis CU1 (CU1) was
grown in LB or MH broth at 30 C and 37 C. A) Hemolytic activity testing. B. subtilis
CU1 cell-free supernatants were incubated with human erythrocytes for 3 h. Bars
represent hemoglobin release measured by absorbance at 415 nm. Positive controls:
SDS and B. cereus 14579 (Bc). B) Cytotoxic activity testing. B. subtilis CU1 cell-free su-
pernatants were added to wells containing Vero cells and incubated for 2 h at 37 C.
Cells were stained with crystal violet dye and absorbance was measured at 650 nm.
Positive controls: B. cereus 14579 (Bc) and C. difﬁcile VPI (Cd) supernatants; negative
control: MH medium. All results are the average of 3 values from independent
experiments ± SD, where (***) indicates a signiﬁcant difference compared to the cor-
responding control (P < 0.001).
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MICs for each antibiotic are shown in Table 2. TheMIC results for
the S. aureus ATCC 29213 reference control strain were in-line with
the quality control ranges set by the Clinical and Laboratory Stan-
dards Institute (CLSI, 2011). The MICs determined for B. subtilis CU1
were compared to the Bacillus break points published by EFSA
(2012) and all concentrations were less than or equal to their
respective break point values.3.3. Assessment of toxigenic activity
The toxigenic potential of B. subtilis CU1 was evaluated by
assessing its hemolytic, surfactant, and cytotoxic activity in vitro(Table 3). Hemolytic activity was evaluated on human erythrocytes
by the addition of cell-free supernatants to fresh, viable erythrocyte
cultures. B. subtilis CU1 cell-free supernatants (from LB or MH
media cultured at 30 or 37 C) did not induce hemolysis of eryth-
rocytes. When erythrocytes were incubated with cell-free super-
natant from B. cereus 14579 cultures or SDS, high levels of
hemoglobin were released from the erythrocytes under all exper-
imental conditions (Fig. 3A, Table 3).
The surfactant activity of B. subtilis CU1 was assessed by the
qualitative drop-collapse method. B. subtilis 13 GR cultures (posi-
tive control) grown in liquid LB andMHmedia produced signiﬁcant
surfactant activity, and some dispersion (slightly spread out) was
also observed when this strain was grown on solid LB medium
(data not shown). Conversely, B. subtilis CU1 grown on solid LB and
MHmedia, as well as liquid LB and MHmedia, did not produce any
metabolites with biosurfactant properties; the drops remained
beaded in all of the test wells and were visually comparable to the
negative control wells (Table 3).
The cytotoxicity of B. subtilis CU1 supernatant was tested on
Vero cells using the crystal violet staining assay to assess cellular
detachment as a measure of viability. Cytotoxicity was observed to
Vero cells exposed to the cell-free supernatants of the positive
controls B. cereus 14579 and C. difﬁcile CD VPI, as indicated by the
signiﬁcant reduction in OD values. Vero cells exposed to the cell-
free supernatant of B. subtilis CU1 grown in liquid media (LB and
MH) at two different temperatures (30 and 37 C) remained viable,
and no difference in OD values relative to the negative control
values was observed (Fig. 3B, Table 3). Results shown in Fig. 3 are
representative of multiple evaluations.
3.4. Clinical safety assessment
Over 16 weeks of B. subtilis CU1 consumption (2  109 spores/
day for 40 days in total), no statistically signiﬁcant trends in the
number of subjects experiencing at least one adverse event were
observed between the probiotic and control groups (51.6% of the
probiotic group, 48.4% of the placebo group, P¼ 0.68) (Table 4). The
likelihood of the adverse events being associated with study
participation, ranked as not likely, possibly, likely, or certainly
related, was no different between the placebo and B. subtilis CU1
groups when assessed based on total events (P ¼ 0.70) as well as
based on only 1 event per subject (P ¼ 0.36). As outlined in Table 5,
3 events in the treatment group were possibly associated with
participation in the study (2 incidents of nasal obstruction episodes
in the same subject and one report of headache in another subject),
and one event was likely related (mild pain for about 10 min after
test capsule consumption) but remained an isolated event. One
case of vasovagal episode during blood sampling was certainly
associated with participation in the study, but was not related to
test article consumption. In the placebo group, only one event, a
headache that appeared minutes after taking the test product and
disappeared over the course of the day, was possibly related to
study participation. The majority of adverse events in both placebo
(98.81%) and probiotic (95.37%) groups were not related to partic-
ipation in the study (Table 4).
The intensity of each adverse event was classiﬁed as mild,
moderate, or severe, and the summary of adverse events by in-
tensity is provided in Table 6. Statistical analysis indicated that
adverse events in the probiotic group were signiﬁcantly more
intense when compared to placebo (P ¼ 0.01) (Table 4). This asso-
ciation was likely due to the fact that 2 subjects in the probiotic
group with known histories of migraines experienced multiple
episodes during the study. Migraines reported by these 2 subjects,
unrelated to treatment, accounted for 40% of the total adverse
events in the probiotic group classiﬁed as moderate. The ﬁrst
Table 4
Summary of adverse event reporting during a 16-week clinical Bacillus subtilis CU1 consumption study.
B. subtilis CU1 (N ¼ 50) Placebo (N ¼ 50) P (95%)
Absolute Relative Absolute Relative
Subjects experiencing:
At least one AE (M/F) 32 (6/26) 51.61% 30 (5/25) 48.39% 0.68b
No AEs (M/F) 18 (4/14) 48.39% 20 (6/14) 52.63%
Association of AEs with study participation:
Unrelated to treatment 103 95.37% 83 98.81% 0.70c
Possibly related 3 2.78% 1 1.19%
Likely related 1 0.93% 0 e
Certainly related 1 0.93% 0 e
Subjects with at least 1 AE:
Unrelated to treatment 28 87.50% 29 96.67% 0.36c
Related to treatmenta 4 12.50% 1 3.33%
Severity of AEs:
Mild 41 37.96% 48 57.14% 0.01c
Moderate 58 53.70% 34 40.48%
Severe 0 e 0 e
Subjects with at least 1 AE, highest severity of mild:
Unrelated to treatment 10 71.43% 10 90.91% 0.34c
Related to treatmenta 4 28.57% 1 9.09%
Subjects with at least 1 AE, highest severity of moderate:
Unrelated to treatment 18 100.0% 19 100.0% N/A
Related to treatmenta 0 0% 0 0%
AE ¼ adverse event; F ¼ female; M ¼ male; N/A ¼ not applicable.
a Events considered possibly, likely, or certainly related to treatment.
b Statistical signiﬁcance determined using the chi-square test.
c Statistical signiﬁcance determined using Fisher's exact test.
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mildly intense and 14 were moderate. The second subject experi-
enced 10 migraine episodes that were all classiﬁed as moderately
intense. One subject in the placebo group with a known history of
migraines experienced 9 migraines during the study, of which 8
were classiﬁed as mildly intense and one was moderate, all unre-
lated to treatment. All adverse events related to treatment in both
placebo (1 event) and probiotic groups (5 events) were mild in
severity, and based on 1 event per subject of highest severity, no
statistical difference was found between the 2 groups with respect
to the mild events being related to treatment (P ¼ 0.34) (Table 4).
All moderate events were unrelated to treatment and no severe
events occurred during the study.
One serious adverse event occurred during the study, unrelated
to study participation, where one subject in the placebo group
required hospitalization for a hallux valgus foot deformity. The
following infections were documented during the study period,
none of which were attributed to participation in the study: one
dental infection, one cutaneous infection, one case of genital her-
pes, and one case of ungual mycosis occurred in the probiotic
group; one case of labial herpes and one case of panaritium
occurred in the placebo group.
The markers of liver and kidney function (ALT, AST, GGT, creat-
inine, and urea) measured at baseline and week 16 were notTable 5
Summary of all adverse events related to treatment.a
Adverse event Probiotic
(N ¼ 50)
Placebo
(N ¼ 50)
Number with at least 1 related AE 4 (8.0%) 1 (2.0%)
Headache 1 (2.0%) 1 (2.0%)
Pain following capsule consumption 1 (2.0%) 0 (0%)
Nasal obstruction 2 (4.0%) 0 (0%)
Vasovagal episode following blood
collection
1 (2.0%) 0 (0%)
AE ¼ adverse event; N ¼ number of subjects.
a Events considered possibly, likely, or certainly related to treatment.signiﬁcantly different between the probiotic and placebo groups at
either time point. Similarly, results of the complete blood count
were not signiﬁcantly different between the groups at baseline or
week 16. Hemodynamic parameters (arterial pressure and heart
rate), likewise, did not show any signiﬁcant differences between
the two groups at baseline, week 8, or week 16, nor any pathologic
variation (Table 7).4. Discussion and conclusion
B. subtilis CU1 is intended for use as a probiotic and therefore the
safety of this ingredient was evaluated based upon the regulatory
guidelines published by EFSA (QPS) and the Joint FAO/WHO Expert
Consultation on Evaluation of Health and Nutritional Properties of
Probiotics in Food. The safety assessment included a series of
in vitro experiments to characterize the new microbial strain and
assess its toxigenic potential, followed by a randomized, double-
blind, placebo-controlled, parallel-arm clinical study.
First, to satisfy QPS status deﬁned by EFSA for the B. subtilis
species, B. subtilis CU1 was identiﬁed at the species and strain level
using a combination of genomic testing techniques. The B. subtilis
species complex consists of an assemblage of closely related species
and it has been long established that the use of phenotypic,
biochemical, and 16S rDNA sequencing are insufﬁcient for
discriminating between species within this complex (Rooney et al.,
2009). Partial sequencing of the ribosomal 16S DNA, up to a
maximum of 1312 base pairs, and comparison of this sequencewith
other Bacillus strains showed strong homology with several Bacillus
species belonging to the B. subtilis group (99%). Using nucleotide
sequence analyses of gyrB, Wang and colleagues have identiﬁed
gyrB as a secondary target for taxonomic identiﬁcation of members
of the B. subtilis complex (Wang et al., 2007). A sequence homology
of 97% and 95% was observed for B. subtilis CU1 gyrB relative to
respective gyrB sequences of Bacillus subtilis subsp. spizizenii and
B. subtilis subsp. subtilis identiﬁed within the NCBI database. As
reported by Wang et al. (2007), strains with 95.5e100% identity
with the gyrB sequence display high DNA-DNA relatedness
Table 6
Summary of all adverse events by intensity.
Adverse event Probiotic (N ¼ 50) Placebo (N ¼ 50)
Mild Moderate Severe Mild Moderate Severe
Abdominal/GI discomfort 1 (1.0) 0 0 5 (6.1) 2 (2.4) 0
Acne rosacea 0 0 0 0 1 (1.2) 0
Anxiety, depression 0 1 (1.0) 0 0 1 (1.2) 0
Arthritic pain 3 (3.0) 0 0 1 (1.2) 0 0
Birthmark excision 0 1 (1.0) 0 0 0 0
Bronchitis 0 1 (1.0) 0 0 0 0
Bruising (following a fall) 1 (1.0) 0 0 0 1 (1.2) 0
Carotid stenosis 0 1 (1.0) 0 0 0 0
Cataract surgery 1 (1.0) 0 0 0 0 0
Chondrocalcinosis 0 1 (1.0) 0 0 0 0
Colonoscopy & ﬁbroscopy 0 0 0 1 (1.2) 0 0
Cystitis 0 2 (2.0) 0 0 0 0
Dental pain 1 (1.0) 4 (4.0) 0 0 2 (2.4) 0
Diarrhea 1 (1.0) 0 0 1 (1.2) 1 (1.2) 0
Dizziness & nausea 0 1 (1.0) 0 0 0 0
General aches 3 (3.0) 0 0 0 0 0
Genital herpes 0 6 (6.1) 0 1 (1.2) 0 0
Headache 9 (9.1) 3 (3.0) 0 11 (13.4) 5 (6.1) 0
Hemorrhoids 0 1 (1.0) 0 0 1 (1.2) 0
Infection 2 (2.0) 1 (1.0) 0 0 3 (3.7) 0
Inﬂamed prostate 0 1 (1.0) 0 0 0 0
Migraine 3 (3.0) 25 (25.3) 0 10 (12.2) 4 (4.9) 0
Mouth ulcer 1 (1.0) 0 0 0 0 0
Muscular discomfort 0 0 0 1 (1.2) 2 (2.4) 0
Nasal obstruction 2 (2.0) 0 0 0 0 0
Orthopedic pain 5 (5.1) 7 (7.1) 0 5 (6.1) 7 (8.5) 0
Pain following capsule consumption 1 (1.0) 0 0 0 0 0
Palpitations 0 0 0 1 (1.2) 0 0
Radio-inﬁltration (shoulder) 1 (1.0) 0 0 0 0 0
Rhinitis 0 1 (1.0) 0 8 (9.8) 0 0
Sore throat 1 (1.0) 0 0 1 (1.2) 0 0
Tracheitis 1 (1.0) 0 0 0 0 0
Trouble sleeping, insomnia 2 (2.0) 1 (1.0) 0 2 (2.4) 2 (2.4) 0
Vaginal dryness 0 0 0 0 2 (2.4) 0
Vasovagal episode (following blood collection) 1 (1.0) 0 0 0 0 0
Vitamin D deﬁciency 1 (1.0) 0 0 0 0 0
Total 41 58 0 48 34 0
GI ¼ gastrointestinal; N ¼ number of subjects.
Data represent total number of adverse events followed by % in brackets.
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larity in the gryB sequence typically exhibit DNA-DNA relatedness
of 60e70% indicating grouping at the subspecies level. Therefore,
based on the results of the 16S rDNA and gryB nucleotide analyses,
B. subtilis CU1 can be identiﬁed at the subspecies level as B. subtilis
subsp. spizizenii.
Identiﬁcation at the strain level is an important element of the
safety assessment of a microorganism as it establishes the identity
of the strain of interest in a similar manner that a speciﬁcation is
used to characterize chemical ingredients, and can be used for
quality control, establishing genomic stability, and post-market
surveillance purposes. Effective discrimination of a probiotic at
the strain level is also critical for conﬁrming the identity of mi-
crobial test articles used in safety studies. In the case of B. subtilis
CU1, strain characterization was effectively achieved through RAPD
PCR analysis that produced consistent DNA ﬁngerprints unique to
the B. subtilis CU1 strain. Thus, RAPD can be used as a fast method to
discriminate between probiotic strains, for example, when
enumerating colonies of a probiotic strain present in fecal samples
(Lefevre et al., 2015), but nevertheless, has its disadvantages as
inter-laboratory reproducibility is characteristically low (Sabat
et al., 2013). On the other hand, PFGE is often considered the gold
standard of molecular typing methods, presenting a high degree of
reproducibility and resolving power, and SﬁI is the most frequently
used enzyme in conventional probiotic Bacillus PFGE protocols (De
Baets et al., 2009). In this study, PFGE analysis of B. subtilis CU1using SﬁI resulted in a unique DNA pattern, and moreover, when
two independent production batches generated in consecutive
years were tested, one identical pattern was obtained. Therefore,
PFGE may be the method of choice to control industrial probiotic
production and for unambiguous B. subtilis CU1 strain
discrimination.
It is generally recognized that all microorganisms used as direct
food ingredients should be evaluated for the potential to harbor
potentially transferable acquired antibiotic resistance traits. The
guidelines set by the EFSA FEEDAP Panel in 2012 (EFSA, 2012)
suggest that the Bacillus species should be tested against the
following antibiotics: vancomycin, gentamycin, kanamycin, strep-
tomycin, erythromycin, clindamycin, tetracycline, and chloram-
phenicol. We were able to demonstrate that B. subtilis CU1 was not
resistant to any of these antibiotics above deﬁned regulatory
thresholds, based upon comparison of the measured MICs with the
microbiological cut-off values listed by EFSA for the Bacillus species
(EFSA, 2012). B. subtilis CU1 was also evaluated for phenotypic ev-
idence of toxigenic activity using three validated in vitro assays and
the results of all tests for hemolytic and cytotoxic activity as well as
biosurfactant production consistently demonstrated a lack of
toxigenicity. As outlined in the safety decision tree proposed by
Pariza et al. (2015), an important and necessary step in the safety
assessment of novel microbial cultures is to sequence the genome
of the new microbial strain, which can then be bioinformatically
searched for genetic factors associated with pathogenicity as well
Table 7
Biological safety parameters assessed during a 16-week clinical Bacillus subtilis CU1 consumption study.
Clinical Chemistry Bacillus subtilis CU1 Placebo
Baseline (N ¼ 50) Week 16 (N ¼ 50) Baseline (N ¼ 50) Week 16 (N ¼ 49)
ALT (mkat/L) 0.30 ± 0.15 0.28 ± 0.12 0.32 ± 0.17 0.29 ± 0.10
AST (mkat/L) 0.35 ± 0.10 0.33 ± 0.09 0.35 ± 0.09 0.34 ± 0.08
GGT (mkat/L) 0.43 ± 0.31 0.38 ± 0.21 0.54 ± 0.41 0.49 ± 0.33
Creatinine (mmol/L) 63.06 ± 10.59 65.00 ± 10.92 63.76 ± 12.61 64.33 ± 11.70
Urea (mmol/L) 5.56 ± 1.54 5.21 ± 1.25 5.91 ± 1.38 5.81 ± 1.32
Hematology Bacillus subtilis CU1 Placebo
Baseline (N ¼ 50) Week 16 (N ¼ 50) Baseline (N ¼ 50) Week 16 (N ¼ 50)
Blood glucose (mmol/L) 5.41 ± 0.49 5.33 ± 0.56 5.35 ± 0.55 5.13 ± 0.57
Leucocytes (x 109/L) 6.08 ± 1.62 5.88 ± 1.74 6.02 ± 1.37 6.13 ± 1.37
Erythrocytes (x 1012/L) 4.56 ± 0.37 4.56 ± 0.34 4.57 ± 0.32 4.52 ± 0.27
Hemoglobin (g/dL) 14.08 ± 1.09 14.10 ± 1.03 14.03 ± 0.89 13.85 ± 0.74
Hematocrit (%) 41.58 ± 3.02 41.20 ± 2.72 41.38 ± 2.58 40.68 ± 2.25
MCV (fL) 91.22 ± 3.49 90.50 ± 3.69 90.65 ± 2.49 90.00 ± 2.48
MCHC (g/dL) 33.87 ± 0.78 34.23 ± 0.69 33.91 ± 0.62 34.07 ± 0.70
RDW (%) 11.87 ± 0.58 11.80 ± 0.51 11.93 ± 0.58 11.89 ± 0.55
Platelets (x 109/L) 280.56 ± 66.30 276.88 ± 67.01 270.88 ± 60.00 283.46 ± 61.27
MPV (fL) 8.28 ± 1.28 8.13 ± 1.31 8.63 ± 1.24 8.29 ± 1.19
Neutrophils (%) 58.44 ± 9.18 57.53 ± 8.84 57.99 ± 8.62 57.25 ± 9.77
Lymphocytes (%) 29.96 ± 8.49 31.07 ± 8.16 30.36 ± 7.91 31.23 ± 8.30
Monocytes (%) 7.87 ± 1.41 7.97 ± 1.77 8.02 ± 1.83 7.47 ± 1.77
Eosinophils (%) 2.66 ± 2.18 2.41 ± 1.58 2.45 ± 1.21 2.92 ± 1.86
Basophils (%) 1.06 ± 0.39 1.03 ± 0.35 1.17 ± 0.46 1.13 ± 0.43
Neutrophils (x 109/L) 3.61 ± 1.30 3.44 ± 1.34 3.53 ± 1.16 3.56 ± 1.22
Lymphocytes (x 109/L) 1.77 ± 0.59 1.79 ± 0.64 1.80 ± 0.53 1.88 ± 0.56
Monocytes (x 109/L) 0.48 ± 0.16 0.46 ± 0.17 0.47 ± 0.10 0.45 ± 0.12
Eosinophils (x 109/L) 0.16 ± 0.16 0.13 ± 0.08 0.15 ± 0.08 0.17 ± 0.11
Basophils (x 109/L) 0.06 ± 0.02 0.06 ± 0.02 0.07 ± 0.03 0.07 ± 0.03
Hemodynamic Parameters Bacillus subtilis CU1 Placebo
Baseline (N ¼ 50) Week 8 (N ¼ 50) Week 16 (N ¼ 50) Baseline (N ¼ 50) Week 8 (N ¼ 50) Week 16 (N ¼ 50)
Systolic arterial pressure (mmHg) 131.7 ± 14.3 129.6 ± 14.5 130.1 ± 13.8 128.3 ± 13.1 129.8 ± 11.2 127.9 ± 12.3
Diastolic arterial pressure (mmHg) 77.3 ± 12.0 78.3 ± 9.3 77.5 ± 11.6 77.8 ± 8.3 80.1 ± 9.0 80.9 ± 8.4
Heart rate (bpm) 74.6 ± 12.2 74.2 ± 11.7 70.8 ± 9.9 69.6 ± 10.2 70.6 ± 10.6 67.6 ± 9.7
ALT ¼ alanine transaminase; AST ¼ aspartate transaminase; GGT ¼ gamma-glutamyltransferase; MCHC ¼ mean corpuscular hemoglobin concentration; MCV ¼ mean
corpuscular volume; MPV ¼ mean platelet volume; RDW ¼ red blood cell distribution width.
All values expressed as mean ± SD.
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sequenced and BLAST software was employed to survey the
genome for genes associated with conferring antibiotic or multi-
drug resistance, as well as genes implicated in biogenic amine (i.e.,
histamine, tryptamine) or enterotoxin (i.e., cytotoxin, haemolysin)
production. Overall, no genetic factors associated with antibiotic or
multidrug resistance as well as biogenic amine or enterotoxin
synthesis were identiﬁed in the B. subtilis CU1 genome (personal
data), conﬁrming the results of the above in vitro assays. Therefore,
based upon the results of the genomic, antimicrobial, and cytotoxic
activity assays, B. subtilis CU1 was concluded to be adequately
characterized and was concluded to be a non-toxigenic strain of
B. subtilis. These measures also satisfy the QPS requirements out-
lined by EFSA for members of the Bacillus species (EFSA, 2015).
In the human study, the daily consumption of B. subtilis CU1
(2 109 spores/day) for 40 days over 16 weeks was found to be safe
and well-tolerated by elderly subjects. B. subtilis CU1 was not
associated with the occurrence of adverse events, both related and
unrelated to treatment, when compared to the placebo group.
Consumption of B. subtilis CU1 was also found to have no effect on
any of the biological safety parameters assessed, and overall, was
safe and well-tolerated by all subjects. The lack of toxicity observed
with B. subtilis CU1 is consistent with the fact that the B. subtilis
species is associated with a long history of safe consumption as
both a dietary supplement and food ingredient in different parts of
the world (Cutting, 2011; Shurtleff, 2012). To date, the consumptionof various strains of B. subtilis by humans has primarily been
through the intake of probiotic mixtures marketed as dietary sup-
plements in Asia, Europe, and the U.S. For example, the probiotic
preparation Medilac® containing B. subtilis R0179 combined with
Enterococcus faecium R0026 has been marketed in Korea since 1994
and in China since 2000 (Tompkins et al., 2010; Dion, 2012). Stan-
dard preparations contain a nine to one ratio of E. faecium R0026 to
B. subtilis R0179, and when taken three times per day, a total of
approximately 3.0  108 CFU of B. subtilis are ingested per day. A
number of post-market clinical studies have been conducted on
this preparation that consistently indicate that consumption of
B. subtilis R0179 is not associated with any toxicological responses
or adverse reactions in humans (Tompkins et al., 2010).
B. subtilis is also associated with a long history of safe use in the
food industry, primarily the consumption of fermented food
products in the Asian and African regions. In Japan, proprietary
variants of B. subtilis have been consumed for decades as a
component of the fermented food product natto. This traditional
food is prepared by fermenting soybeans with B. subtilis and is
believed to have been a component of the Japanese diet as early as
the year 1450 (Shurtleff, 2012). Natto products carry up to 108
viable spores of B. subtilis per gram of product, and its consumption
has been associated with a long history of safe use and beneﬁcial
health effects (Cutting, 2011). Other alkaline-fermented foods
generated by bacterial cultures containing B. subtilis, such as Thai
thua-nao and kinema from cooked soybeans, dawadawa from
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melon seeds, are safely consumed in a number of African and
Southeast Asian countries (Wang and Fung, 1996). B. subtilis also
has a long history of safe use in food enzyme manufacturing and is
one of the most widely employed bacterial species for this appli-
cation (Schallmey et al., 2004).
Interestingly, recent evidence suggests that even in the absence
of consuming food products or dietary supplements that contain
B. subtilis, humans are inherently exposed to this microbe. For
instance, B. subtilis spores have been detected in the gastrointes-
tinal tract and feces of humans that have not intentionally
consumed B. subtilis-containing food products or dietary supple-
ments (Tam et al., 2006; Hong et al., 2009). Fakhry et al. (2008)
isolated spore-forming bacteria from the feces and ileal biopsies
of healthy non-probiotic consuming human volunteers, and of the
25 Bacillus strains isolated, 13 of them were found to belong to the
B. subtilis species. Similarly, Hong et al. (2009) have identiﬁed and
characterized a diverse population of B. subtilis strains residing
within the human gastrointestinal tract. It has been hypothesized
that B. subtilis has been introduced to the human gastrointestinal
tract through the ingestion of plant matter, as these spores inhabit
the upper layers of the soil in great abundance and could become
an intestinal commensal. Nevertheless, from a safety perspective,
whether exposure occurs due to direct or indirect consumption,
any bacteria entering the small and large intestines (viable or dead)
are not expected to translocate into the systemic circulation, as the
gastrointestinal mucosa is impermeable to bacteria in healthy in-
dividuals. Studies in animals speciﬁcally investigating the fate and
dissemination of B. subtilis spores in vivo have demonstrated that
B. subtilis spores administered orally do not appear to cross mucosal
surfaces and are in fact excreted in the feces (Hoa et al., 2001; Duc
et al., 2003).
4.1. Conclusion
The safety of B. subtilis CU1 (CNCM I-2745), a probiotic intended
for human consumption, was evaluated by conducting a series of
in vitro and clinical investigations. Genomic characterization using
16S rDNA and gyrB sequencing conﬁrmed the identity of the or-
ganism as under the species B. subtilis, and classiﬁcation at the
subspecies level as Bacillus subtilis subspecies spizizenii was sug-
gested by the greatest gyrB sequence homology observed with
B. subtilis subsp. spizizenii isolates. Genomic analyses using RAPD
PCR and PFGE were used to further characterize the probiotic at the
strain level. In vitro investigations demonstrated that antibiotic
resistance was not observed at levels exceeding the regulatory cut-
offs set by EFSA and that B. subtilis CU1 was absent of toxigenic
activity. Repeated consumption of B. subtilis CU1 spores was
demonstrated to be safe and did not induce any undesirable
physiological effects or biological safety concerns in adult subjects
consuming 2  109 spores/day for 40 days in total. Based on these
results and on information supporting the long history of safe
consumption of B. subtilis in the diet, we conclude that B. subtilis
CU1 is safe for human consumption.
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